Tecentriq
Authorised
This medicine is authorised for use in the European Union
atezolizumab
MedicineHumanAuthorised
- Application under evaluation
- CHMP opinion
- European Commission decision
Overview
Tecentriq is a medicine used to treat the following cancers:
- urothelial cancer (cancer of the bladder and urinary system);
- non-small cell lung cancer (NSCLC);
- small cell lung cancer (SCLC);
- a type of breast cancer known as triple-negative breast cancer;
- hepatocellular carcinoma, a cancer that starts in the liver.
Tecentriq is used either on its own or in combination with other treatments for cancers that are advanced or have spread to other parts of the body. In some cases, it is used after surgery or after other cancer treatments.
The doctor may need to confirm that the cancer cells produce a certain amount of a protein called PD-L1, and that particular genetic mutations known to reduce the medicine’s effectiveness are not present. For more information about the use of Tecentriq, see the package leaflet.
Tecentriq contains the active substance atezolizumab.
Tecentriq is given as an infusion (drip) into a vein every 2, 3 or 4 weeks, or as an injection under the skin every 3 weeks. Depending on the type of cancer, patients are treated either for one year or for as long as they benefit from treatment, unless they have unmanageable side effects. The doctor may stop treatment if the patient has certain side effects involving the immune system (the body’s defence system), including inflammation of various body organs or endocrine (glandular) disorders. For more information about using Tecentriq, see the package leaflet or contact your doctor or pharmacist.
Tecentriq can only be obtained with a prescription and treatment should be started and supervised by a doctor experienced in treating cancer.
The active substance in Tecentriq, atezolizumab, is a monoclonal antibody (a type of protein) designed to attach to a protein called PD-L1, which is present on many cancer cells.
PD-L1 switches off immune cells that would otherwise attack cancer cells. By attaching to PD-L1, Tecentriq reduces its effects and so increases the immune system’s ability to attack cancer cells and thereby slows down progression of the disease.
Urothelial cancer
Tecentriq can reduce the size of tumours in patients with urothelial cancer that is advanced or has spread. In a study of 429 patients, the cancer shrank or was eliminated after Tecentriq treatment in 23% of patients who were not eligible for platinum chemotherapy and in 16% of patients who had previously had platinum chemotherapy.
In another study involving 931 patients with urothelial cancer, those given Tecentriq lived slightly longer (8.6 months) on average than patients given chemotherapy (8 months) although the difference could be due to chance. Response was seen even in patients whose cancer cells did not produce much PD-L1.
Lung cancer
Non-small cell lung cancer
In patients with non‑small cell lung cancer that is advanced or has spread, Tecentriq is more effective than docetaxel (another cancer medicine) at prolonging patients’ lives. In one main study of 850 patients, those given Tecentriq lived for 14 months on average while those given docetaxel lived for 10 months. In a second study of 287 patients, patients on Tecentriq lived for 13 months on average compared with 10 months for patients on docetaxel.
In another main study of 1,202 patients with advanced non‑small cell lung cancer which has spread and who had not received chemotherapy before, patients given Tecentriq together with paclitaxel, carboplatin and bevacizumab (other cancer medicines) lived on average for 8.4 months without their disease getting worse while those given paclitaxel, carboplatin and bevacizumab lived on average for 6.8 months without their disease getting worse. Overall, patients given Tecentriq with the other medicines lived for 19.8 months on average compared with 14.9 months for patients given the same medicines without Tecentriq.
Another study investigated the effect of Tecentriq in 679 previously untreated patients with NSCLC who did not have a type of cancer known as EGFR mutant or ALK‑positive NSCLC. Patients lived on average for 18.6 months when they were given Tecentriq with carboplatin plus nab-paclitaxel compared with 13.9 months when given the combination without Tecentriq. In addition, patients lived for about 7 months without their disease getting worse when they received the Tecentriq combination compared with 5.5 months without Tecentriq.
In a further study in 205 patients with metastatic non-small cell lung cancer who had not received chemotherapy before, patients treated with Tecentriq lived for 20.2 months on average compared with 14.7 months for those who received platinum-based chemotherapy and either pemetrexed or gemcitabine.
Tecentriq was shown to be effective in patients with early-stage NSCLC without EGFR or ALK mutations in which more than 50% of the cancer cells presented PD-L1 on their surface, and who had undergone surgery to completely remove the cancer before receiving platinum-based therapy. After approximately 32 months, around 77% of patients who received Tecentriq (82 out of 106) had no sign of the cancer coming back, compared with 56% (58 out of 103) of patients who received standard cancer treatments. At the time of authorisation, no benefit was observed in patients with cancer cells that presented lower levels of PD-L1 on their surface.
A further study involved 453 patients with advanced, recurrent or metastatic NSCLC who had not previously received systemic (whole body) treatment and who could not receive platinum-based therapy. They received either Tecentriq or chemotherapy (vinorelbine or gemcitabine). Patients who received Tecentriq lived on average for 10.3 months compared with 9.2 months for those who received chemotherapy.
Small cell lung cancer
In a study of 403 patients with the generally more aggressive small cell lung cancer, patients lived for
12.3 months on average when Tecentriq was added to carboplatin plus etoposide, compared with 10.3 months when placebo (a dummy treatment) was added instead. In addition, patients given the Tecentriq combination lived for 5.2 months on average without their disease getting worse compared with 4.3 months for patients who were not given Tecentriq.
Breast cancer
A study of 902 patients with a type of breast cancer known as triple-negative breast cancer looked at the effect of combining Tecentriq with nab-paclitaxel. Patients whose cancer produced the PD-L1 protein up to a certain level lived for an average of 25 months on the Tecentriq plus nab-paclitaxel combination compared with 18 months when given placebo plus nab-paclitaxel. Patients in the Tecentriq group also lived for longer without their disease getting worse (7.5 months versus 5.3).
Hepatocellular carcinoma
A study involved 501 patients with hepatocellular carcinoma that had spread and had not been treated previously. Patients treated with Tecentriq in combination with bevacizumab lived on average for 6.8 months without their disease getting worse, compared to 4.3 months for patients treated with sorafenib.
For the full list of side effects and restrictions with Tecentriq, see the package leaflet.
The side effects of Tecentriq are mostly related to the activity of the immune system, which may cause inflammation of body organs and tissues and can be serious. The most common side effects with Tecentriq when used on its own (which may affect more than 1 in 10 people) include tiredness, reduced appetite, nausea (feeling sick), vomiting, cough, dyspnoea (difficulty breathing), diarrhoea, rash, fever, headache, pain in the back or joints, weakness, itching and urinary tract (structures that carry urine) infection.
The most common side effects with Tecentriq when used with other cancer medicines (which may affect more than 2 in 10 people) include peripheral neuropathy (nerve damage in the hands and feet), nausea, anaemia (low red blood cell counts), neutropenia (low white blood cell counts), alopecia (loss of hair), thrombocytopenia (low platelet counts), rash, tiredness, constipation, reduced appetite and diarrhoea.
In addition, when Tecentriq is given as an injection under the skin, reaction at the site of injection may occur in up to 1 in 10 people.
In urothelial cancer, Tecentriq has been shown to reduce tumour size in patients who have been treated with platinum chemotherapy or who are not eligible for such treatment. Tecentriq can also prolong the time patients with lung cancer, triple-negative breast cancer and hepatocellular carcinoma live.
Tecentriq’s side effects when used alone are less troublesome than standard chemotherapy treatments. When Tecentriq is used in combination with other cancer medicines, the side effects are more severe but are considered manageable.
The European Medicines Agency therefore decided that Tecentriq’s benefits are greater than its risks
and it can be authorised for use in the EU.
The company that markets Tecentriq provides an educational programme for patients and healthcare professionals to explain that serious immune-related side effects can occur during treatment and what they should do to minimise risks.
Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Tecentriq have also been included in the summary of product characteristics and the package leaflet.
As for all medicines, data on the use of Tecentriq are continuously monitored. Side effects reported with Tecentriq are carefully evaluated and any necessary action taken to protect patients.
Tecentriq received a marketing authorisation valid throughout the EU on 21 September 2017.
Product information
Latest procedure affecting product information:
VR/0000272433
16/06/2025
This medicine’s product information is available in all official EU languages.
Select 'available languages' to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
Product details
- Name of medicine
- Tecentriq
- Active substance
- atezolizumab
- International non-proprietary name (INN) or common name
- atezolizumab
- Therapeutic area (MeSH)
- Carcinoma, Transitional Cell
- Carcinoma, Non-Small-Cell Lung
- Urologic Neoplasms
- Breast Neoplasms
- Small Cell Lung Carcinoma
- Anatomical therapeutic chemical (ATC) code
- L01XC32
Pharmacotherapeutic group
Antineoplastic agentsTherapeutic indication
Urothelial carcinoma
Tecentriq as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (UC):
- after prior platinum containing chemotherapy, or
- who are considered cisplatin ineligible, and whose tumours have a PD-L1 expression ≥ 5% (see section 5.1).
Early-stage non-small cell lung cancer (NSCLC)
Tecentriq as monotherapy is indicated as adjuvant treatment following complete resection and platinum-based chemotherapy for adult patients with NSCLC with a high risk of recurrence whose tumours have PD-L1 expression on ≥ 50% of tumour cells (TC) and who do not have EGFR mutant or ALK positive NSCLC (see section 5.1 for selection criteria).
Advanced NSCLC
Tecentriq, in combination with bevacizumab, paclitaxel and carboplatin, is indicated for the first-line treatment of adult patients with metastatic non-squamous non small cell lung cancer (NSCLC). In patients with EGFR mutant or ALK-positive NSCLC, Tecentriq, in combination with bevacizumab, paclitaxel and carboplatin, is indicated only after failure of appropriate targeted therapies (see section 5.1).
Tecentriq, in combination with nab paclitaxel and carboplatin, is indicated for the first line treatment of adult patients with metastatic non-squamous NSCLC who do not have EGFR mutant or ALK positive NSCLC (see section 5.1).
Tecentriq as monotherapy is indicated for the first-line treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumours have a PD-L1 expression ≥ 50% tumour cells (TC) or ≥ 10% tumour-infiltrating immune cells (IC) and who do not have EGFR mutant or ALK-positive NSCLC (see section 5.1).
Tecentriq as monotherapy is indicated for the first-line treatment of adult patients with advanced NSCLC who are ineligible for platinum-based therapy (see section 5.1 for selection criteria).
Tecentriq as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic NSCLC after prior chemotherapy. Patients with EGFR mutant or ALK positive NSCLC should also have received targeted therapies before receiving Tecentriq (see section 5.1).
Small cell lung cancer (SCLC)
Tecentriq, in combination with carboplatin and etoposide, is indicated for the first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC) (see section 5.1).
Triple-negative breast cancer (TNBC)
Tecentriq in combination with nab-paclitaxel is indicated for the treatment of adult patients with unresectable locally advanced or metastatic TNBC whose tumours have PD-L1 expression ≥ 1% and who have not received prior chemotherapy for metastatic disease.
Hepatocellular carcinoma
Tecentriq, in combination with bevacizumab, is indicated for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma (HCC) who have not received prior systemic therapy (see section 5.1).
Urothelial carcinoma (UC)
Tecentriq as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic UC:
- after prior platinum containing chemotherapy, or
- who are considered cisplatin ineligible, and whose tumours have a PD-L1 expression ≥ 5% (see section 5.1).
Early-stage non-small cell lung cancer (NSCLC)
Tecentriq as monotherapy is indicated as adjuvant treatment following complete resection and platinum-based chemotherapy for adult patients with NSCLC with a high risk of recurrence whose tumours have PD-L1 expression on ≥ 50% of tumour cells (TC) and who do not have EGFR mutant or ALK positive NSCLC (see section 5.1 for selection criteria).
Advanced NSCLC
Tecentriq, in combination with bevacizumab, paclitaxel and carboplatin, is indicated for the first-line treatment of adult patients with metastatic non-squamous NSCLC. In patients with EGFR mutant or ALK-positive NSCLC, Tecentriq, in combination with bevacizumab, paclitaxel and carboplatin, is indicated only after failure of appropriate targeted therapies (see section 5.1).
Tecentriq, in combination with nab paclitaxel and carboplatin, is indicated for the first line treatment of adult patients with metastatic non-squamous NSCLC who do not have EGFR mutant or ALK positive NSCLC (see section 5.1).
Tecentriq as monotherapy is indicated for the first-line treatment of adult patients with metastatic NSCLC whose tumours have a PD-L1 expression ≥ 50% TC or ≥ 10% tumour-infiltrating immune cells (IC) and who do not have EGFR mutant or ALK-positive NSCLC (see section 5.1).
Tecentriq as monotherapy is indicated for the first-line treatment of adult patients with advanced NSCLC who are ineligible for platinum-based therapy (see section 5.1 for selection criteria).
Tecentriq as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic NSCLC after prior chemotherapy. Patients with EGFR mutant or ALK positive NSCLC should also have received targeted therapies before receiving Tecentriq (see section 5.1).
Small cell lung cancer (SCLC)
Tecentriq, in combination with carboplatin and etoposide, is indicated for the first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC) (see section 5.1).
Triple-negative breast cancer (TNBC)
Tecentriq in combination with nab-paclitaxel is indicated for the treatment of adult patients with unresectable locally advanced or metastatic TNBC whose tumours have PD-L1 expression ≥ 1% and who have not received prior chemotherapy for metastatic disease.
Hepatocellular carcinoma (HCC)
Tecentriq, in combination with bevacizumab, is indicated for the treatment of adult patients with advanced or unresectable HCC who have not received prior systemic therapy (see section 5.1).
Assessment history
News on Tecentriq
Topics
This page was last updated on